JP2003509066A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003509066A5 JP2003509066A5 JP2001523800A JP2001523800A JP2003509066A5 JP 2003509066 A5 JP2003509066 A5 JP 2003509066A5 JP 2001523800 A JP2001523800 A JP 2001523800A JP 2001523800 A JP2001523800 A JP 2001523800A JP 2003509066 A5 JP2003509066 A5 JP 2003509066A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- bank
- cells
- gene
- treated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 description 38
- 210000004027 cell Anatomy 0.000 description 24
- 108020004707 nucleic acids Proteins 0.000 description 22
- 102000039446 nucleic acids Human genes 0.000 description 22
- 150000007523 nucleic acids Chemical class 0.000 description 22
- 150000001875 compounds Chemical class 0.000 description 19
- 108090000623 proteins and genes Proteins 0.000 description 16
- 238000009396 hybridization Methods 0.000 description 10
- 230000006907 apoptotic process Effects 0.000 description 8
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 7
- 239000002853 nucleic acid probe Substances 0.000 description 7
- 239000000523 sample Substances 0.000 description 6
- 230000001640 apoptogenic effect Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 230000004913 activation Effects 0.000 description 3
- 230000002074 deregulated effect Effects 0.000 description 3
- 230000003831 deregulation Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 231100000721 toxic potential Toxicity 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 108020005196 Mitochondrial DNA Proteins 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000007674 genetic toxicity Effects 0.000 description 2
- 231100000025 genetic toxicology Toxicity 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- AFWRJOYNLMVZQO-GMFATLNBSA-N (1r,2r,4as,8as)-1-[(1e,3e)-5-hydroxy-3-methylpenta-1,3-dienyl]-2,5,5,8a-tetramethyl-3,4,4a,6,7,8-hexahydro-1h-naphthalen-2-ol Chemical compound CC1(C)CCC[C@]2(C)[C@@H](/C=C/C(=C/CO)/C)[C@](C)(O)CC[C@H]21 AFWRJOYNLMVZQO-GMFATLNBSA-N 0.000 description 1
- 102100034682 26S proteasome regulatory subunit 7 Human genes 0.000 description 1
- 108010029607 4-nitrophenyl-alpha-glucosidase Proteins 0.000 description 1
- 102000006589 Alpha-ketoglutarate dehydrogenase Human genes 0.000 description 1
- 108020004306 Alpha-ketoglutarate dehydrogenase Proteins 0.000 description 1
- 102100034501 Cyclin-dependent kinases regulatory subunit 1 Human genes 0.000 description 1
- 230000022963 DNA damage response, signal transduction by p53 class mediator Effects 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 102100034690 Delta(14)-sterol reductase LBR Human genes 0.000 description 1
- 102000003817 Fos-related antigen 1 Human genes 0.000 description 1
- 108090000123 Fos-related antigen 1 Proteins 0.000 description 1
- 102000001390 Fructose-Bisphosphate Aldolase Human genes 0.000 description 1
- 108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 description 1
- 102000012215 HSC70 Heat-Shock Proteins Human genes 0.000 description 1
- 108010036652 HSC70 Heat-Shock Proteins Proteins 0.000 description 1
- 101710113864 Heat shock protein 90 Proteins 0.000 description 1
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 description 1
- 101001090865 Homo sapiens 26S proteasome regulatory subunit 7 Proteins 0.000 description 1
- 101000710200 Homo sapiens Cyclin-dependent kinases regulatory subunit 1 Proteins 0.000 description 1
- 101001033293 Homo sapiens Interleukin enhancer-binding factor 3 Proteins 0.000 description 1
- 101001109052 Homo sapiens NADH-ubiquinone oxidoreductase chain 4 Proteins 0.000 description 1
- 101000628647 Homo sapiens Serine/threonine-protein kinase 24 Proteins 0.000 description 1
- 101000707561 Homo sapiens Splicing factor 3A subunit 2 Proteins 0.000 description 1
- 101000597043 Homo sapiens Transcriptional enhancer factor TEF-5 Proteins 0.000 description 1
- 101000828889 Homo sapiens tRNA modification GTPase GTPBP3, mitochondrial Proteins 0.000 description 1
- 102100039062 Interleukin enhancer-binding factor 3 Human genes 0.000 description 1
- 102000045959 Interleukin-1 Receptor-Like 1 Human genes 0.000 description 1
- 108700003107 Interleukin-1 Receptor-Like 1 Proteins 0.000 description 1
- 102100033421 Keratin, type I cytoskeletal 18 Human genes 0.000 description 1
- 108010066327 Keratin-18 Proteins 0.000 description 1
- 101150026369 MT-ND6 gene Proteins 0.000 description 1
- 101000954570 Mus musculus V-type proton ATPase 16 kDa proteolipid subunit c Proteins 0.000 description 1
- 102100021506 NADH-ubiquinone oxidoreductase chain 4 Human genes 0.000 description 1
- 102100028386 NADH-ubiquinone oxidoreductase chain 6 Human genes 0.000 description 1
- 101150090932 ND6 gene Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000005877 Peptide Initiation Factors Human genes 0.000 description 1
- 108010044843 Peptide Initiation Factors Proteins 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 description 1
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 1
- 102100026764 Serine/threonine-protein kinase 24 Human genes 0.000 description 1
- 102100031712 Splicing factor 3A subunit 2 Human genes 0.000 description 1
- 102100035147 Transcriptional enhancer factor TEF-5 Human genes 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 108010091356 Tumor Protein p73 Proteins 0.000 description 1
- 102000018252 Tumor Protein p73 Human genes 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000037442 genomic alteration Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 108010022838 lamin B receptor Proteins 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000001324 spliceosome Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9911405A FR2798392B1 (fr) | 1999-09-13 | 1999-09-13 | Marqueurs genetiques de la toxicite, preparation et utilisations |
| FR99/11405 | 1999-09-13 | ||
| PCT/FR2000/002503 WO2001020029A2 (fr) | 1999-09-13 | 2000-09-12 | Marquers genetiques de la toxicite, preparation et utilisations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003509066A JP2003509066A (ja) | 2003-03-11 |
| JP2003509066A5 true JP2003509066A5 (enExample) | 2007-11-08 |
Family
ID=9549766
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001523800A Pending JP2003509066A (ja) | 1999-09-13 | 2000-09-12 | 遺伝学的毒性マーカー、その調製及び使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US6509153B1 (enExample) |
| EP (1) | EP1220950B9 (enExample) |
| JP (1) | JP2003509066A (enExample) |
| AT (1) | ATE263255T1 (enExample) |
| AU (1) | AU783310B2 (enExample) |
| CA (1) | CA2380383A1 (enExample) |
| DE (1) | DE60009530T2 (enExample) |
| DK (1) | DK1220950T3 (enExample) |
| ES (1) | ES2216958T3 (enExample) |
| FR (1) | FR2798392B1 (enExample) |
| IL (1) | IL148615A0 (enExample) |
| PT (1) | PT1220950E (enExample) |
| WO (1) | WO2001020029A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6881571B1 (en) * | 1998-03-11 | 2005-04-19 | Exonhit Therapeutics S.A. | Qualitative differential screening |
| FR2798673B1 (fr) * | 1999-09-16 | 2004-05-28 | Exonhit Therapeutics Sa | Methodes et compositions pour la detection d'evenements pathologiques |
| US7361488B2 (en) * | 2000-02-07 | 2008-04-22 | Illumina, Inc. | Nucleic acid detection methods using universal priming |
| WO2003018792A1 (en) * | 2001-08-24 | 2003-03-06 | National Institute Of Advanced Industrial Science And Technology | Method of detecting toxic substance |
| GB0410105D0 (en) * | 2004-05-06 | 2004-06-09 | Amersham Biosciences Uk Ltd | Method for characterising compounds |
| EP1856283A2 (en) * | 2005-03-09 | 2007-11-21 | DSMIP Assets B.V. | Method for measuring and comparing the activity of biologically active compounds |
| BRPI0718413A2 (pt) * | 2006-10-23 | 2014-03-11 | Uab Research Foundation | Métodos para prever a sensibilidade de uma célula concerosa a um primeiro agente anticâncer, para prever ou monitorar a eficácia de um agente anticâncer, e para determinar uma dose eficaz para um agente anticâncer, kit de detecção, e, sistema de ensaio multiplex |
| DE102010024898B4 (de) * | 2010-06-24 | 2012-10-25 | Merck Patent Gmbh | Genexpressionsanalysen zur Charakterisierung und Identifizierung genotoxischer Verbindungen |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4965188A (en) * | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
| US5985549A (en) * | 1985-10-22 | 1999-11-16 | University Of Massachusetts | Non-isotopic in-situ hybridization method for detection of nucleic acids |
| US4888278A (en) * | 1985-10-22 | 1989-12-19 | University Of Massachusetts Medical Center | In-situ hybridization to detect nucleic acid sequences in morphologically intact cells |
| US5057410A (en) * | 1988-08-05 | 1991-10-15 | Cetus Corporation | Chimeric messenger RNA detection methods |
| US5143854A (en) * | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US6309822B1 (en) * | 1989-06-07 | 2001-10-30 | Affymetrix, Inc. | Method for comparing copy number of nucleic acid sequences |
| US5474796A (en) * | 1991-09-04 | 1995-12-12 | Protogene Laboratories, Inc. | Method and apparatus for conducting an array of chemical reactions on a support surface |
| US5674682A (en) * | 1992-10-29 | 1997-10-07 | Thomas Jefferson University | Nucleic acid primers for detecting micrometastasis of prostate cancer |
| US5521297A (en) * | 1993-06-04 | 1996-05-28 | Salk Institute Biotechnology/Industrial Associates | Nucleic acids encoding human metabotropic glutamate receptors |
| US5837832A (en) * | 1993-06-25 | 1998-11-17 | Affymetrix, Inc. | Arrays of nucleic acid probes on biological chips |
| US5529925A (en) * | 1993-12-03 | 1996-06-25 | St. Jude Children's Research Hospital | Nucleic acid sequences and fusion proteins present in human t(2;5) lymphoma |
| US5484702A (en) * | 1994-01-27 | 1996-01-16 | Research Foundation Of The State University Of New York At Buffalo | Method for preselecting recombinant clones containing a specific nucleic acid sequence and subsequent transformation with preselected clones |
| US5679541A (en) * | 1994-02-14 | 1997-10-21 | California Institute Of Technology | Programmed cell death antagonist protein |
| PH31414A (en) * | 1994-02-24 | 1998-10-29 | Boehringer Ingelheim Int | Method of diagnosing cancer precancerous state, orsusceptibility to other forms of diseases by anal ysis of irf-1 specific rna in biopsy samples. |
| US5767258A (en) * | 1995-05-12 | 1998-06-16 | The Johns Hopkins University School Of Medicine | Cell cycle regulatory gene |
| WO1997013877A1 (en) * | 1995-10-12 | 1997-04-17 | Lynx Therapeutics, Inc. | Measurement of gene expression profiles in toxicity determination |
| US5922535A (en) * | 1995-11-07 | 1999-07-13 | Huo; Li | Identifying sequence differences in nucleic acid populations |
| FR2775984B1 (fr) * | 1998-03-11 | 2006-09-15 | Bioscreen Therapeutics Sa | Criblage differentiel qualitatif |
| US6881571B1 (en) * | 1998-03-11 | 2005-04-19 | Exonhit Therapeutics S.A. | Qualitative differential screening |
| FR2755984B1 (fr) * | 1996-11-15 | 2002-12-27 | Bourachot Philippe | Borne escamotable |
| US6060240A (en) * | 1996-12-13 | 2000-05-09 | Arcaris, Inc. | Methods for measuring relative amounts of nucleic acids in a complex mixture and retrieval of specific sequences therefrom |
| CA2225187A1 (en) * | 1997-07-14 | 1999-01-14 | Universite D'ottawa/ University Of Ottawa | Xaf genes and polypeptides: methods and reagents for modulating apoptosis |
| US6849400B1 (en) * | 1997-07-23 | 2005-02-01 | Gen-Probe Incorporated | Methods for detecting and measuring spliced nucleic acids |
| GB9717766D0 (en) * | 1997-08-22 | 1997-10-29 | Zeneca Ltd | Methods |
| AU750187B2 (en) * | 1997-09-17 | 2002-07-11 | Johns Hopkins University, The | P53-induced apoptosis |
| DE69925362T2 (de) * | 1998-02-23 | 2006-01-19 | Phylonix Pharmaceuticals Inc., Cambridge | Screeningverfahren für die aktivität von agenzien unter verwendung von teleosten |
| JPH11262621A (ja) * | 1998-03-17 | 1999-09-28 | Ebara Corp | 除湿空調装置 |
| US6168920B1 (en) * | 1998-08-10 | 2001-01-02 | Incyte Genomics, Inc. | Extracellular adhesive proteins |
| US6160105A (en) * | 1998-10-13 | 2000-12-12 | Incyte Pharmaceuticals, Inc. | Monitoring toxicological responses |
| EP1108067A2 (en) * | 1998-08-28 | 2001-06-20 | Incyte Pharmaceuticals, Inc. | Toxicological response markers |
| FR2798673B1 (fr) * | 1999-09-16 | 2004-05-28 | Exonhit Therapeutics Sa | Methodes et compositions pour la detection d'evenements pathologiques |
| US7981844B2 (en) * | 2001-06-21 | 2011-07-19 | Verenium Corporation | Methods for the manufacture of pure single enantiomer compounds and for selecting enantioselective enzymes |
-
1999
- 1999-09-13 FR FR9911405A patent/FR2798392B1/fr not_active Expired - Fee Related
- 1999-12-08 US US09/456,370 patent/US6509153B1/en not_active Expired - Fee Related
-
2000
- 2000-09-12 AU AU74269/00A patent/AU783310B2/en not_active Ceased
- 2000-09-12 WO PCT/FR2000/002503 patent/WO2001020029A2/fr not_active Ceased
- 2000-09-12 AT AT00962602T patent/ATE263255T1/de not_active IP Right Cessation
- 2000-09-12 IL IL14861500A patent/IL148615A0/xx unknown
- 2000-09-12 PT PT00962602T patent/PT1220950E/pt unknown
- 2000-09-12 CA CA002380383A patent/CA2380383A1/fr not_active Abandoned
- 2000-09-12 DK DK00962602T patent/DK1220950T3/da active
- 2000-09-12 JP JP2001523800A patent/JP2003509066A/ja active Pending
- 2000-09-12 EP EP00962602A patent/EP1220950B9/fr not_active Expired - Lifetime
- 2000-09-12 ES ES00962602T patent/ES2216958T3/es not_active Expired - Lifetime
- 2000-09-12 DE DE60009530T patent/DE60009530T2/de not_active Expired - Lifetime
-
2001
- 2001-03-22 US US10/070,676 patent/US20030059788A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1064404B1 (en) | P53-regulated genes | |
| Zhu et al. | RORA, a large common fragile site gene, is involved in cellular stress response | |
| Bauer et al. | Protamine mRNA as molecular marker for spermatozoa in semen stains | |
| Jowsey et al. | Expression of the aflatoxin B1-8, 9-epoxide-metabolizing murine glutathione S-transferase A3 subunit is regulated by the Nrf2 transcription factor through an antioxidant response element | |
| WO1995021944A1 (en) | Differentially expressed genes in healthy and diseased subjects | |
| KR20040010401A (ko) | 안드로겐 수용체 복합체-결합 단백질 | |
| Dötsch et al. | Gene expression of neuronal nitric oxide synthase and adrenomedullin in human neuroblastoma using real‐time PCR | |
| JP2003509066A5 (enExample) | ||
| JP2002521067A (ja) | ヒトのｕｄｐ−グルクロノシルトランスフェラーゼ２ｂ４（ｕｇｔ２ｂ４）、２ｂ７（ｕｇｔ２ｂ７）及び２ｂ１５（ｕｇｔ２ｂ１５）遺伝子の遺伝子型決定 | |
| Okamoto et al. | Polymorphism of 5-methylcytosine-rich DNA in human acrocentric chromosomes | |
| AU783310B2 (en) | Genetic markers of toxicity, preparation and uses thereof | |
| Escaig-Haye et al. | Analysis of human mitochondrial transcripts using electron microscopic in situ hybridization | |
| US20030165931A1 (en) | Qualitative differential screening | |
| US7091033B2 (en) | Array of toxicologically relevant canine genes and uses thereof | |
| Meltzer et al. | Identification of region specific genes by chromosome microdissection | |
| Shiue | Identification of candidate genes for drug discovery by differential display | |
| EP1501949A2 (en) | Ssh based methods for identifying and isolating unique nucleic acid sequences | |
| KR20190136107A (ko) | ＵＶ 관련된 ｍｔＤＮＡ 융합 전사체 및 이의 방법 및 용도 | |
| CA2075259A1 (en) | Expression cloning method | |
| Assad et al. | Immunogold electron microscopy in situ end‐labeling (EM‐ISEL): Assay for biomaterial DNA damage detection | |
| Randolph | Acute promyelocytic leukemia (AML-M3)-part 2: molecular defect, DNA diagnosis, and proposed models of leukemogenesis and differentiation therapy | |
| Boily et al. | In vivo footprinting analysis of the Glypican 3 (GPC3) promoter region in neuroblastoma cells | |
| JP2001509662A (ja) | 疾患特異的遺伝子の定量および発見のための高容量ｉｎ―ｓｉｔｕ ｍＲＮＡ ハイブリダイゼーション法 | |
| WO2003016560A2 (en) | Methods for diagnosing and treating neoplasias using nf-at transcription factors | |
| Wang et al. | [16] Identification and characterization of transcription factors from mammalian cells |